methyl 2-(tert-butoxycarbonylamino)-2-methyl-3-phenylpropanoate | 159090-39-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 2-(tert-butoxycarbonylamino)-2-methyl-3-phenylpropanoate
• 英文别名: Methyl 2-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoate
• CAS: 159090-39-8
• 化学式: C₁₆H₂₃NO₄
• 分子量: 293.363
• InChiKey: BBGOHLUPPAZPPQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  21
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  BOC-L-丙氨酸甲酯 、 溴甲苯 在 quinuclidine N-oxide 、 叔丁基锂 作用下， 以 四氢呋喃 、 hexanes 为溶剂， 反应 12.0h， 以46%的产率得到methyl 2-(tert-butoxycarbonylamino)-2-methyl-3-phenylpropanoate
  参考文献：
  名称：

  The synthesis of functionalised peptides using α-lithio quinuclidine N-oxide (Li-QNO)

  摘要：

  Deprotonation of protected peptides using lithiated quinuclidine N-oxide (Li-QNO) as a base at 0 degrees C, followed by addition of an alkyl halide gives C-alkylated peptide derivatives in good yield. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2009.03.105

文献信息

• Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
  申请人：Nantermet G. Philippe

  公开号：US20070088165A1

  公开（公告）日：2007-04-19

  The present invention is directed to benzylether and benzylamino derivative compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

  本发明涉及式(I)的苯甲醚和苯甲氨基衍生物化合物，它们是β-分泌酶酶的抑制剂，并且在治疗β-分泌酶酶涉及的疾病，例如阿尔茨海默病中有用。本发明还涉及包含这些化合物的制药组合物以及在治疗β-分泌酶酶涉及的疾病中使用这些化合物和组合物的用途。
• BENZYLETHER AND BENZYLAMINO BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER S DISEASE
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP1689713B1

  公开（公告）日：2011-07-27
• N-HALOGENATED AMINO COMPOUNDS AND DERIVATIVES
  申请人：NovaBay Pharmaceuticals, Inc.

  公开号：EP2120965B1

  公开（公告）日：2014-11-05
• US7354942B2
  申请人：——

  公开号：US7354942B2

  公开（公告）日：2008-04-08
• US8415497B2
  申请人：——

  公开号：US8415497B2

  公开（公告）日：2013-04-09